← Leaderboards
Han Xiao
Rice University
$5,388,907
Attributed
$8,214,173
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,214,173 · 4
By mechanism
R01$5,082,127 · 2
R35$2,563,640 · 1
R21$568,406 · 1
Top collaborators
- Mohamed Abdel Mohsen6 shared
- Jason Yustein3 shared
- Xiang Zhang3 shared
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsEnzymesAntibodiesIn VivoSiteDesignPreventMedicineExhibitsCancer CellMalignant NeoplasmsTumorTreatment EfficacyBindingGenerationsGenetic CodeCollectionPharmaceutical PreparationsProgramsImmuneAntibody ConjugateIn VitroT-LymphocytePhenotype
Grant awards (19)
Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis$652,042
R01 · FY2025 · CA · contact PI
Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection$608,916
R01 · FY2025 · AI
Engineering Proteins with Noncanonical Amino Acids$381,190
R35 · FY2025 · GM · contact PI
Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis$619,441
R01 · FY2024 · CA · contact PI
Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection$408,072
R01 · FY2024 · AI
Engineering Proteins with Noncanonical Amino Acids$381,190
R35 · FY2024 · GM · contact PI
Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection$270,230
R01 · FY2024 · AI
Modulation of Epigenetic Target in the Bone to Treat Breast Cancer Metastasis$666,169
R01 · FY2023 · CA · contact PI
Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection$633,402
R01 · FY2023 · AI
Development and Applications of Unnatural Organisms with a 21 Amino Acid Genetic Code$378,416
R35 · FY2023 · GM · contact PI
Development of Bone-Targeting Antibodies for Ewing Sarcoma Using Genetic Code Expansion$171,527
R21 · FY2023 · CA · contact PI
Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection$607,040
R01 · FY2022 · AI
Development and Applications of Unnatural Organisms with a 21 Amino Acid Genetic Code$378,416
R35 · FY2022 · GM · contact PI
Development of Bone-Targeting Antibodies for Ewing Sarcoma Using Genetic Code Expansion$171,527
R21 · FY2022 · CA · contact PI
Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection$616,815
R01 · FY2021 · AI
Development and Applications of Unnatural Organisms with a 21 Amino Acid Genetic Code$378,416
R35 · FY2021 · GM · contact PI
Development of Bone-Targeting Antibodies for Ewing Sarcoma Using Genetic Code Expansion$225,352
R21 · FY2021 · CA · contact PI
Development and Applications of Unnatural Organisms with a 21 Amino Acid Genetic Code$333,006
R35 · FY2020 · GM · contact PI
Development and Applications of Unnatural Organisms with a 21 Amino Acid Genetic Code$333,006
R35 · FY2019 · GM · contact PI